SCHEMBL78000

SCHEMBL78000

COC(=O)Cc1ccccn1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.53
ALDH1A1 P00352 5/20 0.51
CYP1A2 P05177 2/20 0.51
TSHR P16473 1/20 0.51
RAB9A P51151 4/20 0.50
POLB P06746 2/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
NPC1 O15118 2/20 0.50
LMNA P02545 2/20 0.49
PKM P14618 1/20 0.49
KDM4E B2RXH2 3/20 0.48
CYP2C19 P33261 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
APOBEC3G Q9HC16 1/20 0.47
ALOX15 P16050 1/20 0.47
HSD17B10 Q99714 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29390571 1.00 SMN1; SMN2 (0.53) SMN1; SMN2ALDH1A1CYP1A2TSHRRAB9A
Hydrochloric Acid SCHEMBL7500894 0.98 SMN1; SMN2 (0.51) SMN1; SMN2ALDH1A1CYP1A2TSHRRAB9A
Water SCHEMBL7798110 0.98 SMN1; SMN2 (0.51) SMN1; SMN2ALDH1A1CYP1A2TSHRRAB9A
Methyl Alcohol SCHEMBL3396777 0.87 ALDH1A1 (0.53) SMN1; SMN2ALDH1A1CYP1A2TSHRRAB9A
Nitrobenzene SCHEMBL28101568 0.85 KMT2A (0.55) ALDH1A1CYP1A2RAB9APOLBMEN1
SCHEMBL375765 0.85 RAB9A (0.53) SMN1; SMN2ALDH1A1CYP1A2TSHRRAB9A
SCHEMBL2769178 0.82 SMN1; SMN2 (0.52) SMN1; SMN2ALDH1A1CYP1A2TSHRRAB9A
Acetic Acid SCHEMBL6285526 0.82 ALDH1A1 (0.53) SMN1; SMN2ALDH1A1CYP1A2TSHRRAB9A
SCHEMBL30858931 0.82 LMNA (0.56) SMN1; SMN2ALDH1A1CYP1A2TSHRRAB9A
SCHEMBL134991 0.82 LMNA (0.56) SMN1; SMN2ALDH1A1CYP1A2TSHRRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 446 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3363788-A1 CANNABINOID RECEPTOR MODULATORS Arena Pharmaceuticals, Inc. (US) 2018-08-22 EP claimed
US-20130165412-A1 CANNABINOID RECEPTOR MODULATORS ARENA PHARMACEUTICALS, INC. 2013-06-27 US claimed
US-20120214766-A1 CANNABINOID RECEPTOR MODULATORS ARENA PHARMACEUTICALS, INC. 2012-08-23 US claimed
EP-2470508-A1 CANNABINOID RECEPTOR MODULATORS Arena Pharmaceuticals, Inc. (US) 2012-07-04 EP claimed
WO-2011025541-A1 CANNABINOID RECEPTOR MODULATORS ARENA PHARMACEUTICALS, INC. (US) 2011-03-03 WO claimed
US-20020025477-A1 Non-aqueous electrolytic solution and secondary battery containing same MITSUBISHI CHEMICAL CORPORATION (JP) 2002-02-28 US claimed
EP-1172878-A2 Non-aqueous electrolytic solution and secondary battery containing same MITSUBISHI CHEMICAL CORPORATION (JP) 2002-01-16 EP claimed
US-12629359-B2 Structural analogues of methylphenidate as Parkinson's disease-modifying agents UNIVERSITA' DEGLI STUDI DI BRESCIA (IT) 2026-05-19 US disclosed
US-12605450-B2 C3-carbon linked glutarimide Degronimers for target protein degradation C4 THERAPEUTICS, INC. (US) 2026-04-21 US disclosed
EP-4709725-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF Progentos Therapeutics, Inc. (US) 2026-03-18 EP disclosed
US-20250367158-A1 MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88 ACADIA PHARM INC (US) 2025-12-04 US disclosed
US-20250367143-A1 MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88 ACADIA PHARM INC (US) 2025-12-04 US disclosed
US-20250313567-A1 IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS INCYTE CORPORATION 2025-10-09 US disclosed
US-4396606-A OPIATE ANTAGONISTS ADDICTION RESEARCH FOUNDATION (US) 1983-08-02 US disclosed
EP-0060144-A2 Cephalosporin antibiotics ELI LILLY AND COMPANY (US) 1982-09-15 EP disclosed
EP-0029300-A1 Polypeptides, antisera containing them and methods of their use Addiction Research Foundation (US) 1981-05-27 EP disclosed
US-4001241-A GASTRIC ACID, ANTISECRETORY AGENTS SMITHKLINE CORPORATION (US) 1977-01-04 US disclosed
US-3966945-A 2-Alkoxy(and 2-alkoxyalkyl)-2-heterocyclic-thioacetamides for inhibiting gastric acid secretion SMITHKLINE CORPORATION (US) 1976-06-29 US disclosed
US-3956494-A ANTISECRETORY AGENTS, HETEROCYCLIC THIOPROPIONAMIDES SMITHKLINE CORPORATION (US) 1976-05-11 US disclosed
US-3948892-A 2-Alkoxy(and 2-amino)-3-amino-2-heterocyclic-thiopropanamides SMITHKLINE CORPORATION (US) 1976-04-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120214766-A1 CANNABINOID RECEPTOR MODULATORS CNR1, CNR2, TRPV1 SMN1; SMN2 208/4885ALDH1A1 3623/4885CYP1A2 2151/4885
US-12605450-B2 C3-carbon linked glutarimide Degronimers for target protein degradation NEDD4, UBE3A, UBE3C SMN1; SMN2 3245/4885ALDH1A1 3454/4885CYP1A2 3960/4885
US-20250367143-A1 MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88 GPR88, GPR84, GPR68 SMN1; SMN2 2618/4885ALDH1A1 2684/4885CYP1A2 2876/4885
US-12629359-B2 Structural analogues of methylphenidate as Parkinson's disease-modifying agents SNCA, SYNJ1, PARK7 SMN1; SMN2 64/4885ALDH1A1 1408/4885CYP1A2 3051/4885
US-20250367158-A1 MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88 GPR88, GPR68, HTR2A SMN1; SMN2 2089/4885ALDH1A1 2000/4885CYP1A2 2531/4885
US-20250313567-A1 IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS ADORA2A, ADORA2B, ADORA1 SMN1; SMN2 1489/4885ALDH1A1 347/4885CYP1A2 137/4885
US-20130165412-A1 CANNABINOID RECEPTOR MODULATORS CNR1, CNR2, TRPV1 SMN1; SMN2 208/4885ALDH1A1 3623/4885CYP1A2 2151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.